The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of cabozantinib (cabo) plus durvalumab (durva) in chemotherapy refractory microsatellite stable (MSS) patients with advanced gastric and esophageal (G/E) adenocarcinoma: CAMILLA G/E cohort results.
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Robin Park
No Relationships to Disclose
 
Junqiang Dai
No Relationships to Disclose
 
Anup Kasi
Consulting or Advisory Role - Ipsen
Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
 
Lori Barbosa
No Relationships to Disclose
 
Kelly Mulvaney
No Relationships to Disclose
 
Jordan Rarden
No Relationships to Disclose
 
Milind A. Phadnis
No Relationships to Disclose
 
Azhar Saeed
No Relationships to Disclose
 
Ibrahim Halil Sahin
Consulting or Advisory Role - GlaxoSmithKline
 
Joaquina Celebre Baranda
No Relationships to Disclose
 
Stephen K. Williamson
Stock and Other Ownership Interests - Horizon Therapeutics; Iovance Biotherapeutics; Merus
Research Funding - Acceleron Pharma (Inst); Aleon Pharma (Inst); Astellas Pharma (Inst); Bayer Health (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Merck Serono (Inst); Nektar (Inst); Novartis (Inst); Pharmacyclics (Inst); Regeneron (Inst); Rogosin Institute (Inst); Sanofi (Inst); Seagen (Inst); Sotio (Inst)
 
Weijing Sun
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Macrogenics
Research Funding - AstraZeneca (Inst); Merck (Inst); Novella Clinical (Inst)
 
Raed Moh'd Taiseer Al-Rajabi
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Seagen
Consulting or Advisory Role - AstraZeneca; Bayer
Speakers' Bureau - Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lexicon (Inst); Lilly (Inst); Merck (Inst); Sillajen (Inst)